Sec Form 4 Filing - Fleurant John @ FGL Holdings - 2020-06-01

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Fleurant John 2. Issuer Name and Ticker or Trading Symbol FGL Holdings [ FG] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Financial Officer (Last) (First) (Middle) 4TH FLOOR, BOUNDARY HALL, CRICKET SQUARE 3. Date of Earliest Transaction (MM/DD/YY) 06/01/2020 (Street) GRAND CAYMAN, PRE9KY1-1102 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Employee Stock Option (right to buy) $ 10 06/01/2020 D 1,500,000 ( 1 ) 03/15/2025 Ordinary Shares 1,500,000 ( 2 ) 0 D Employee Stock Option (right to buy) $ 9.18 06/01/2020 D 200,000 ( 3 ) 03/15/2025 Ordinary Shares 200,000 ( 2 ) 0 D Employee Stock Option (right to buy) $ 10 06/01/2020 D 300,000 ( 4 ) 03/15/2025 Ordinary Shares 300,000 ( 2 ) 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Fleurant John 4TH FLOOR BOUNDARY HALL, CRICKET SQUARE GRAND CAYMAN, PRE9KY1-1102 Chief Financial Officer Signatures /s/ Tessa Cantonwine, Attorney-in-Fact 06/03/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Stock option granted pursuant to the Issuer's 2017 Omnibus Incentive Plan, with the following vesting terms: (i) one third of the award vests in five equal annual installments beginning on March 15, 2021, (ii) one third of the award becomes exercisable, if at all, in five equal installments upon the later of (a) the average daily closing price of the Issuer's ordinary shares during any 20 consecutive trading days meeting or exceeding five specified hurdles of $14.75, $17.00, $20.00, $22.00 and $24.00, respectively, and (b) the end of five one year periods ending March 15, 2021, 2022, 2023, 2024 and 2025, respectively, and (iii) one third of the award becomes exercisable, if at all, in three equal annual installments if the Issuer's return on equity meets or exceeds specified annual hurdles of 16.00% for the one year period ending December 31, 2022, 16.25% for the one year period ending December 31, 2023 and 16.50% for the one year period ending December 31, 2024. ( 2 )Issuer and Fidelity National Financial, Inc. ("FNF") entered into an Agreement and Plan of Merger dated effective February 7, 2020 (the "Merger Agreement"), pursuant to which FNF acquired Issuer on June 1, 2020 (the "Merger"). This option was converted in the Merger into an option to purchase shares of FNF Common Stock, all in accordance with the Merger Agreement. ( 3 )Stock option granted pursuant to the 2017 Omnibus Incentive Plan, with the following vesting terms: (i) one third of the award vests in five equal annual installments beginning on March 15, 2021, (ii) one third of the award becomes exercisable, if at all, in five equal installments upon the later of (a) the average daily closing price of the Issuer's ordinary shares during any 20 consecutive trading days meeting or exceeding five specified hurdles of $14.75, $17.00, $20.00, $22.00 and $24.00, respectively, and (b) the end of five one year periods ending March 15, 2021, 2022, 2023, 2024 and 2025, respectively, and (iii) one third of the award becomes exercisable, if at all, in three equal annual installments if the Issuer's return on equity meets or exceeds specified annual hurdles of 16.00% for the one year period ending December 31, 2022, 16.25% for the one year period ending December 31, 2023 and 16.50% for the one year period ending December 31, 2024. ( 4 )Stock option granted pursuant to the 2017 Omnibus Incentive Plan, with the following vesting terms: (i) one half of the award becomes exercisable, if at all, in five equal annual installments if the average daily closing price of the Issuer's ordinary shares for 20 consecutive trading days meets or exceeds specified annual price hurdles of $17.00 for the one year period ending March 15, 2021, $21.00 for the one year period ending March 15, 2022, $25.00 for the one year period ending March 15, 2023, $27.00 for the one year period ending March 15, 2024 and $29.00 for the one year period ending March 15, 2025, respectively, and (ii) one half of the award becomes exercisable, if at all, in three equal annual installments if the Issuer's return on equity meets or exceeds specified annual hurdles of 18.50% for the one year period ending December 31, 2022, 18.75% for the one year period ending December 31, 2023 and 19.00% for the one year period ending December 31, 2024.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.